降钙素基因相关肽单克隆抗体治疗偏头痛患者的椎动脉夹层：一例报告及FAERS数据库分析
Vertebral artery dissection in a patient with migraine treated with calcitonin gene-related peptide monoclonal antibody: a case report and FAERS database analysis.
作者信息
Tokuyasu Daiki, Imai Shungo, Chen Shih-Pin, Ihara Keiko, Watanabe Narumi, Izawa Yoshikane, Nakahara Jin, Hori Satoko, Takizawa Tsubasa
机构信息
Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
出版信息
BMC Neurol. 2025 Jan 2;25(1):1. doi: 10.1186/s12883-024-04009-z.
BACKGROUND
Migraine is associated with cervical artery dissection (CeAD). Calcitonin gene-related peptide (CGRP) is a multifunctional neuropeptide with vasodilatory effects. The use of anti-CGRP monoclonal antibodies (CGRP mAb) may affect cerebrovascular disease risk; however, no reports have associated CGRP mAb with CeAD.
CASE PRESENTATION AND FAERS DATABASE ANALYSIS
We report a case of vertebral artery dissection in a 39-year-old woman with migraine treated with galcanezumab. We searched the number of cases where cerebral and cervical artery dissection were reported as adverse effects of CGRP mAb using the FDA Adverse Event Reporting System (FAERS) database. Six and ten such cases were reported regarding galcanezumab and CGRP mAbs use, respectively. The reporting odds ratios for galcanezumab and CGRP mAbs were elevated.
CONCLUSION
Although migraine is reported to be associated with CeAD, the use of CGRP mAb might be related to CeAD and warrant further investigation.
背景
偏头痛与颈内动脉夹层（CeAD）有关。降钙素基因相关肽（CGRP）是一种具有血管舒张作用的多功能神经肽。抗CGRP单克隆抗体（CGRP mAb）的使用可能会影响脑血管疾病风险；然而，尚无报道将CGRP mAb与CeAD相关联。
病例报告与FAERS数据库分析：我们报告了一例39岁偏头痛女性患者在接受加卡尼单抗治疗后发生椎动脉夹层的病例。我们使用美国食品药品监督管理局不良事件报告系统（FAERS）数据库搜索了将脑动脉和颈内动脉夹层报告为CGRP mAb不良反应的病例数。分别有6例和10例此类病例报告与加卡尼单抗和CGRP mAb的使用有关。加卡尼单抗和CGRP mAb的报告比值比有所升高。
结论
尽管据报道偏头痛与CeAD有关，但CGRP mAb的使用可能与CeAD有关，值得进一步研究。
Zotero 插件